AnaptysBio, Inc.

NasdaqGS:ANAB Stock Report

Market Cap: US$1.1b

AnaptysBio Valuation

Is ANAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ANAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ANAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ANAB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ANAB?

Key metric: As ANAB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ANAB. This is calculated by dividing ANAB's market cap by their current revenue.
What is ANAB's PS Ratio?
PS Ratio6.5x
SalesUS$169.47m
Market CapUS$1.06b

Price to Sales Ratio vs Peers

How does ANAB's PS Ratio compare to its peers?

The above table shows the PS ratio for ANAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.6x
CVAC CureVac
2x-31.06%US$1.2b
STOK Stoke Therapeutics
6.3x-4.92%US$1.3b
DAWN Day One Biopharmaceuticals
7.5x32.24%US$923.1m
ASMB Assembly Biosciences
14.6x13.67%US$485.6m
ANAB AnaptysBio
6.5x18.95%US$1.1b

Price-To-Sales vs Peers: ANAB is expensive based on its Price-To-Sales Ratio (6.5x) compared to the peer average (5.8x).

Price to Sales Ratio vs Industry

How does ANAB's PS Ratio compare vs other companies in the US Biotechs Industry?

151 CompaniesPrice / SalesEstimated GrowthMarket Cap
AMGN Amgen
4.8x1.85%US$169.94b
REGN Regeneron Pharmaceuticals
4.7x6.81%US$66.37b
BIIB Biogen
2.3x-1.78%US$22.99b
INCY Incyte
4.3x2.02%US$20.65b
ANAB 6.5xIndustry Avg. 10.7xNo. of Companies151PS020406080100+
151 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ANAB is good value based on its Price-To-Sales Ratio (6.5x) compared to the US Biotechs industry average (11.2x).

Price to Sales Ratio vs Fair Ratio

What is ANAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ANAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.5x
Fair PS Ratio2.5x

Price-To-Sales vs Fair Ratio: ANAB is expensive based on its Price-To-Sales Ratio (6.5x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ANAB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$39.65
US$68.09
+71.73%
23.74%US$100.00US$36.00n/a11
Nov ’26US$36.58
US$65.73
+79.68%
27.36%US$90.00US$20.00n/a11
Oct ’26US$31.97
US$51.91
+62.37%
39.46%US$90.00US$20.00n/a11
Sep ’26US$20.33
US$49.55
+143.71%
42.47%US$90.00US$20.00n/a11
Aug ’26US$24.69
US$49.00
+98.46%
44.03%US$90.00US$18.00n/a11
Jul ’26US$22.65
US$42.55
+87.84%
46.17%US$90.00US$18.00n/a11
Jun ’26US$22.23
US$41.09
+84.84%
49.89%US$90.00US$18.00n/a11
May ’26US$21.70
US$37.64
+73.44%
37.73%US$57.00US$18.00n/a11
Apr ’26US$18.40
US$37.64
+104.55%
37.73%US$57.00US$18.00n/a11
Mar ’26US$16.82
US$37.09
+120.52%
38.12%US$57.00US$18.00n/a11
Feb ’26US$17.93
US$35.70
+99.11%
38.47%US$59.00US$18.00n/a10
Jan ’26US$13.24
US$35.70
+169.64%
38.47%US$59.00US$18.00n/a10
Dec ’25US$24.96
US$54.36
+117.80%
32.67%US$90.00US$30.00n/a11
Nov ’25US$21.68
US$55.64
+156.63%
32.98%US$90.00US$30.00US$36.5811
Oct ’25US$34.81
US$54.27
+55.91%
32.00%US$80.00US$23.00US$31.9711
Sep ’25US$38.09
US$54.27
+42.49%
32.00%US$80.00US$23.00US$20.3311
Aug ’25US$34.08
US$48.90
+43.49%
36.75%US$80.00US$20.00US$24.6910
Jul ’25US$24.61
US$43.78
+77.89%
41.34%US$80.00US$20.00US$22.659
Jun ’25US$23.94
US$43.78
+82.86%
41.34%US$80.00US$20.00US$22.239
May ’25US$26.02
US$43.50
+67.18%
40.24%US$80.00US$20.00US$21.7010
Apr ’25US$21.32
US$41.50
+94.65%
45.59%US$80.00US$20.00US$18.408
Mar ’25US$25.45
US$40.00
+57.17%
50.02%US$80.00US$20.00US$16.828
Feb ’25US$24.25
US$27.00
+11.34%
34.43%US$44.00US$20.00US$17.935
Jan ’25US$21.42
US$27.00
+26.05%
34.43%US$44.00US$20.00US$13.245
Dec ’24US$15.00
US$27.00
+80.00%
34.43%US$44.00US$20.00US$24.965
Nov ’24US$16.54
US$26.80
+62.03%
37.27%US$45.00US$18.00US$21.685
US$68.09
Fair Value
41.8% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/07 01:36
End of Day Share Price 2025/11/07 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AnaptysBio, Inc. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Neena Bitritto-GargBaird
Etzer DaroutBarclays
Michael KingCitizens JMP Securities, LLC